Metropolis Healthcare Reports Q2 Financial Results; External Quality Services Business Transfer Faces Delay
Metropolis Healthcare Limited has released its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also confirmed updates regarding ongoing business transfers, acquisitions, and employee incentive plans.The Board of Directors approved the financial results, which were noted alongside a limited review report issued by Statutory Auditors.
Standalone Financial Performance Highlights (Q2 FY26)
Metropolis Healthcare Ltd.'s standalone performance for the quarter ended June 30, 2026, showed key figures across various periods.The following table provides a detailed overview of the unaudited standalone financial results in millions of rupees:
| Particulars | 30 June 2026 (Unaudited) | 31 March 2026 (Audited) | 30 June 2025 (Unaudited) | 31 March 2026 (Audited) |
|---|---|---|---|---|
| Income | ||||
| Revenue from operations | 3,722.84 | 3,520.31 | 3,232.69 | 13,654.72 |
| Other income | 51.86 | 88.17 | 27.79 | 163.31 |
| Total Income | 3,774.70 | 3,608.48 | 3,260.48 | 13,818.03 |
| Expenses | ||||
| Cost of materials consumed | 684.74 | 608.18 | 613.58 | 2,527.18 |
| Laboratory testing charges | 67.68 | 56.90 | 40.55 | 180.18 |
| Employee benefits expense | 52.43 | 749.28 | 722.69 | 2,974.38 |
| Finance costs | 473.00 | 65.61 | 42.93 | 191.87 |
| Depreciation and amortisation expense | 278.06 | 327.97 | 278.60 | 1,161.67 |
| Other expenses | 1,180.30 | 1,204.43 | 1,088.29 | 4,590.75 |
| Total Expenses | 3,110.94 | 3,012.37 | 2,786.64 | 11,626.03 |
| Profit before exceptional items and tax | 663.76 | 596.11 | 473.84 | 2,192.00 |
Consolidated Financial Results Summary (Q2 FY26)
The Group's consolidated results reflect the performance of the Parent company and its various subsidiaries across multiple geographies.Key figures from the unaudited consolidated financial results for the quarter ended June 30, 2026, are presented below:
| Particulars | 30 June 2026 (Unaudited) | 31 March 2026 (Audited) | 30 June 2025 (Unaudited) | 31 March 2026 (Audited) |
|---|---|---|---|---|
| Income | ||||
| Revenue from operations | 4,502.15 | 4,246.82 | 3,860.63 | 16,458.46 |
| Other income | 51.02 | 81.62 | 75.16 | 255.84 |
| Total Income | 4,553.17 | 4,328.44 | 3,935.79 | 16,714.30 |
| Expenses | ||||
| Cost of materials consumed | 871.01 | 784.82 | 790.49 | 3,245.17 |
| Laboratory testing charges | 63.30 | 43.07 | 56.74 | 230.05 |
| Employee benefits expense | 1,069.76 | 954.67 | 922.79 | 3,773.65 |
| Finance costs | 61.80 | 79.33 | 31.98 | 245.44 |
| Depreciation and amortisation expense | 324.03 | 385.90 | 308.45 | 1,337.22 |
| Other expenses | 324.03 | 385.90 | 308.45 | 1,337.22 |
| Total Expenses | 1,386.15 | 1,384.08 | 1,193.04 | 5,201.14 |
Operational and Strategic Updates
The Board meeting noted specific updates concerning the business structure and activities:- Business Transfer Status: The sale and transfer of External Quality Assessment Services Business to Metropolis Quality Solutions Private Limited, a wholly owned subsidiary, was originally scheduled for completion within six months of a February 4, 2026 Business Transfer Agreement. It is now expected to take an additional two months.
- Acquisitions: The company has maintained several strategic acquisitions:
2. Scientific Metropolis Pathology Private Limited (formerly Metropolis Clinical Pathology Private Limited) was established through an agreement with Dr. Ashok Kumar Sharma, and the purchase consideration was finalized at Rs 645.00 millions. This transaction saw Dr. Ashok Kumar Sharma acquire a 10% equity stake in Scientific Metropolis, leading it to cease being a wholly owned subsidiary.
3. A Business Transfer Agreement (BTA) was signed with Dr. Rajendra Sadashiv Patil for the acquisition of pathology laboratories located in Kolhapur, which completed on September 18, 2025, for a purchase consideration of Rs 170.00 millions.
- Employee Incentives and Restructuring: During the quarter, the Nomination and Remuneration Committee approved grants including 14,236 Restricted Stock Units (RSU) under the Metropolis Restrictive Stock Unit Plan 2025, and 2,12,345 Employees Stock Options under the Metropolis Employees Stock Option Plan 2025. Additionally, the company issued and allotted 15,54,95,826 Bonus Equity Shares in a 3:1 ratio, following approval by shareholders on March 8, 2026.
- Labour Code Impact: The company assessed the impact of India's four notified Labour Codes (effective from April 1, 2026) and presented the incremental statutory impact as 'Statutory impact of new Labour Codes' under Exceptional Items in the financial results for the quarter and year ended March 31, 2026.
METROPOLIS Stock Price Movement
Shares of Metropolis Healthcare Limited today slipped by 1.1% to close at ₹584.50. The stock saw a trading range throughout the session, hitting an intraday low of ₹581.4 and a high of ₹597.35 amid a volume of 165,890 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: